Relacorilant and nab-paclitaxel for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—relacorilant, which may help chemotherapy work better, and nab-paclitaxel, a type of chemotherapy—for people with cervical cancer that has come back or spread. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that is squamous cell, adenosquamous, or adenocarcinoma type.
- Your cancer has come back or spread, and you've already had one line of chemotherapy that included a platinum drug (like cisplatin or carboplatin), with or without bevacizumab.
- You've had immunotherapy (like pembrolizumab) if your doctor said it was appropriate.
- You've had no more than 3 prior treatments for advanced disease, and you haven't had more than one type of single-agent chemo or one antibody-drug conjugate.
- You haven't had weekly paclitaxel before, except as part of your first treatment with a platinum combo.
- You have tumors that can be measured on scans, and you're willing to provide a tumor sample from a biopsy or surgery.
- You are at least 18 years old, assigned female at birth, and your daily activities are not too limited (ECOG 0 or 1).
- Your blood counts and organ function are within acceptable ranges, and you're not pregnant or breastfeeding.
- You don't have certain conditions like active inflammatory bowel disease, severe nerve damage, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs together for people with cervical cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease better than current options.
This study tests a new drug combination for people with advanced cervical cancer that has spread or returned after platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
This study tests a combination of two chemotherapy drugs (nab-paclitaxel and cisplatin) given alongside radiation therapy for people with locally advanced cervical cancer. The goal is to see if this combination is safe and effective in shrinking the cancer and improving outcomes.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.